About innovent biologics - IVBXF
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
IVBXF At a Glance
Innovent Biologics, Inc.
168 Dongping Street
Suzhou, Jiangsu 215123
| Phone | 86-512-69566088 | Revenue | 1.31B | |
| Industry | Pharmaceuticals: Major | Net Income | -13,149,006.36 | |
| Sector | Health Technology | 2024 Sales Growth | 49.459% | |
| Fiscal Year-end | 12 / 2025 | Employees | N/A | |
| View SEC Filings |
IVBXF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.857 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | 5.329 |
| Total Debt to Enterprise Value | 0.056 |
IVBXF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 8.068 |
| Total Asset Turnover | 0.446 |
IVBXF Liquidity
| Current Ratio | 2.351 |
| Quick Ratio | 2.163 |
| Cash Ratio | 1.805 |
IVBXF Profitability
| Gross Margin | 83.971 |
| Operating Margin | 1.546 |
| Pretax Margin | -0.399 |
| Net Margin | -1.004 |
| Return on Assets | -0.448 |
| Return on Equity | -0.738 |
| Return on Total Capital | -0.601 |
| Return on Invested Capital | -0.621 |
IVBXF Capital Structure
| Total Debt to Total Equity | 21.659 |
| Total Debt to Total Capital | 17.803 |
| Total Debt to Total Assets | 13.152 |
| Long-Term Debt to Equity | 18.426 |
| Long-Term Debt to Total Capital | 15.146 |